Synopsis: Five small-cap stocks including Paras Defence and Space Technologies Ltd, and four others surged over 50% in the past month, driven by strong investor interest, sectoral momentum, and sustained buying in high-growth counters.
Small-cap stocks across defence, pharmaceuticals, specialty healthcare, and fintech segments witnessed strong momentum, supported by robust sectoral tailwinds and sustained investor interest in high-growth, innovation-led businesses. These sectors benefited from increased demand visibility and positive sentiment in niche market categories.
The rally was further driven by heightened participation in emerging technology-driven companies, export-oriented pharmaceutical players, and niche defence and digital services firms, reflecting broader optimism toward small-cap growth stories with strong earnings potential and structural demand support.
Paras Defence and Space Technologies Ltd
Paras Defence and Space Technologies is engaged in designing and manufacturing defence and space engineering products, including optics, defence electronics, and space applications. The company benefits from India’s growing focus on indigenous defence production and increasing orders from space and strategic sectors.
With a market capitalisation of Rs. 11,094 cr, the shares of Paras Defence and Space Technologies closed at Rs. 1376.75 per share, down from its previous close of Rs. 1,410.60 per share. The stock delivered a return of 68% over the past month.
Venus Remedies Ltd
Venus Remedies is a pharmaceutical company involved in the development, manufacturing, and marketing of injectable formulations and antibiotics. It has a strong presence in critical care and specialty segments and also exports its products to multiple international markets.
With a market capitalisation of Rs. 2,267 cr, the shares of Venus Remedies Ltd closed at Rs. 1696 per share, down from its previous close of Rs. 1,759.40 per share. The stock delivered a return of 55% over the past month.
Sigma Advanced Systems Ltd
Sigma Advanced Systems operates in the defence electronics and systems space, focusing on advanced solutions such as command systems, communication equipment, and mission-critical defence technologies. The company is positioned to benefit from rising defence modernisation and government-led procurement initiatives.
With a market capitalisation of Rs. 9,718 cr, the shares of Sigma Advanced Systems Ltd closed at Rs. 551.45 per share, up from its previous close of Rs. 525.20 per share. The stock delivered a return of 58% over the past month.
Network People Services Technologies Ltd
Network People Services Technologies operates in the fintech and digital payments space, providing technology-driven payment solutions, including prepaid payment instruments and digital financial services. The company benefits from India’s rapid shift toward cashless transactions and digital banking adoption.
With a market capitalisation of Rs. 3,224 cr, the shares of Network People Services Technologies Ltd closed at Rs. 1546.40 per share, down from its previous close of Rs. 1,577.20 per share. The stock delivered a return of 52% over the past month.
Bliss GVS Pharma Ltd
Bliss GVS Pharma is a pharmaceutical company specialising in suppositories, oral solids, and gynecology-focused formulations. It has a strong export presence and continues to expand its footprint across regulated and semi-regulated international markets.
With a market capitalisation of Rs. 5,006 cr, the shares of Bliss GVS Pharma Ltd closed at Rs. 473.30 per share, down from its previous close of Rs. 486.60 per share. The stock delivered a return of 56% over the past month.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
